RASGRF2-AS1

Across TCGA pan-cancer cohorts, RASGRF2-AS1 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated RASGRF2-AS1 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RASGRF2-AS1 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated RASGRF2-AS1 expression acts as an unfavorable survival marker, although some lineages such as LIHC and SKCM show a favorable association.

LIHC, KICH, and SKCM are the cancer types where RASGRF2-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	III,IV	0.732	0.168	.002	29	view →
KICH	DFS	Tertile	All	0.769	1.000	.016	23	view →
SKCM	DFS	Median	IV	0.675	0.213	.002	23	view →
ESCA	OS	Median	III,IV	0.594	0.330	.011	17	view →
READ	OS	Median	II,III,IV	0.866	0.334	.004	17	view →
THYM	DFS	Tertile	III,IV	1.000	0.341	.008	12	view →
ACC	DFS	Quartile	IV	0.048	0.535	.001	12	view →
MESO	DFS	Quartile	IV	0.862	0.208	.006	12	view →
HNSC	DFS	Median	IV	0.412	0.250	.009	12	view →
LGG	DFS	Median	All	0.909	0.780	.004	10	view →
THCA	DFS	Quartile	IV	0.933	0.435	.013	10	view →
BRCA	DFS	Tertile	II,III,IV	0.856	0.917	.028	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

RASGRF2-AS1–LIHC (DFS)

Open the LIHC breakdown →